Skip to content
Open access

First-line systemic treatment patterns and outcomes in lung cancer patients with malignant pleural effusion: a retrospective multicenter study

Sep 2026 · Journal of Thoracic Disease · Vol 18 · 0 citations · 45 references
Medicine

Abstract

Background Malignant pleural effusion (MPE) is a frequent complication of advanced lung cancer with poor prognosis. The optimal first-line systemic treatment for these patients remains unclear. This study aimed to evaluate first-line systemic treatment patterns and outcomes in lung cancer patients with MPE. Methods This multicenter retrospective study across 27 centers in China evaluated the efficacy and safety of first-line systemic therapy in lung cancer patients with MPE from 2013 to 2024. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Results Of 1,029 patients included, 88.1% had non-small cell lung cancer (NSCLC) and 11.9% had small cell lung cancer (SCLC); 87.4% received first-line systemic therapy. SCLC patients received chemotherapy alone (50.8%; 62/122) or combined with immunotherapy (47.5%; 58/122). Most driver gene-positive NSCLC patients received targeted therapy (91.4%; 415/454). Driver gene-negative NSCLC patients primarily received chemotherapy alone (27.8%; 126/453), chemotherapy plus immunotherapy (15.9%; 72/453), or chemotherapy plus bevacizumab (17.9%; 81/453). Median OS for the overall cohort was 26.1 months. Systemic therapy significantly extended median OS compared to no systemic therapy (28.1 vs. 12.7 months; P<0.001). Driver gene-positive NSCLC had longer OS than driver gene-negative patients (34.1 vs. 22.6 months; P<0.001). In SCLC, no significant PFS or OS difference was observed between the two regimens. After adjustment, targeted combination therapy versus monotherapy showed non-significant trends for PFS [hazard ratio (HR), 0.74; P=0.09] and OS (HR, 0.67; P=0.10) among driver gene-positive NSCLC. Among driver gene-negative NSCLC, chemotherapy plus bevacizumab significantly improved median OS versus chemotherapy alone (41.8 vs. 21.4 months; P=0.04) and was an independent predictor of favorable OS [HR, 0.59; 95% confidence interval (CI): 0.38–0.90; P=0.02], despite no significant PFS improvement (HR, 0.72; 95% CI: 0.51–1.01; P=0.055), with a manageable safety profile [grade ≥3 treatment-related adverse events (TRAEs): 14.8%]. Conclusions First-line systemic therapy was associated with improved survival in lung cancer patients with MPE, though outcomes differed according to histologic and molecular subtypes. The addition of bevacizumab to chemotherapy was independently associated with longer OS among patients with driver gene-negative NSCLC with MPE.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.